Drug Trial News

RSS

African AIDS drug trial stopped prematurely

One of the studies in three African countries where women were given an AIDS drug to prevent HIV infection is being stopped because the project is not working, researchers said Monday. These women on the trial were taking a daily dose of the drug Truvada or a look-alike placebo pill and had an equal chance of becoming infected. The ones taking Truvada were expected to have had a much lower infection rate.

19 Apr 2011

NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction

NeuroVive Pharmaceutical and Hospices Civils de Lyon today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction.

19 Apr 2011

Positive interim anemia response data from YM's CYT387 Phase I/II trial in myelofibrosis

YM BioSciences Inc., today announced that updated interim anemia response data were reported for the first 60 patients enrolled in the Phase I/II trial of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis.

19 Apr 2011

Circassia closes $98 million fundraising for lead allergy programmes

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has closed a GBP60 million fundraising. The funding round was led by Imperial Innovations, and included investments from other existing shareholders, including Invesco Perpetual.

19 Apr 2011

Novartis NVA23 Phase III trial in COPD achieves primary end point

Sosei Group Corporation announces that NVA237, a long-acting muscarinic antagonist being investigated as a once daily treatment for chronic obstructive pulmonary disease, achieved its primary end point in a Phase III study.

19 Apr 2011

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the publication of a case report in the peer-reviewed Journal of Clinical Oncology documenting the use of tamibarotene in the successful treatment of a patient with recurrent advanced-stage acute promyelocytic leukemia.

19 Apr 2011

Japan Tobacco and Torii commence ferric citrate Phase 3 clinical program for hyperphosphatemia

Keryx Biopharmaceuticals, Inc., announced today that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd., JT's pharmaceutical business subsidiary, has commenced the Phase 3 clinical program of ferric citrate in Japan for the treatment of patients with hyperphosphatemia.

18 Apr 2011

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus in a phase I clinical study.

18 Apr 2011

Positive results from Nabriva's BC-3781 Phase II trial in ABSSSI

Nabriva Therapeutics today announced the successful results of a Phase II clinical trial of BC-3781 in acute bacterial skin and skin structure infections.

18 Apr 2011

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101.

18 Apr 2011

GRAVITAS study shows no benefit of double-dose compared with standard-dose clopidogrel

An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the "one-size fits all" strategy of uniformly doubling the dose of an antiplatelet drug, clopidogrel, for patients with high on-treatment platelet reactivity does not reduce the incidence on death, heart attacks and stent thrombosis after percutaneous coronary intervention.

16 Apr 2011

Data of ImmunoCellular's lead dendritic cell cancer vaccine candidate for GBM presented at AAN meeting

ImmunoCellular Therapeutics, Ltd., announced that Surasak Phuphanich, MD, Principal Investigator of the Phase I clinical trial of ImmunoCellular's lead dendritic cell cancer vaccine candidate for glioblastoma multiforme presented safety and preliminary efficacy data yesterday at the American Academy of Neurology 63rd Annual Meeting.

16 Apr 2011

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

Amylin Pharmaceuticals, Inc. today announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy.

16 Apr 2011

New results from largest multicenter clinical trial for heart transplant patients be released at ISHLT 2011

New results from the largest multicenter clinical trial for heart transplant patients will be released this week at the International Society for Heart & Lung Transplantation 31st Annual Meeting and Scientific Sessions in San Diego. Results show clinical benefit for the use of Everolimus in heart transplant patients.

16 Apr 2011

Opexa's Tovaxin Phase IIb study data in MS presented at AAN meeting

Opexa Therapeutics, Inc., a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis, today presented important efficacy data at the American Academy of Neurology 63rd Annual Meeting.

16 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.

15 Apr 2011

Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children

International biotechnology firm Cytonet recently launched the first ever clinical trial in the United States using an investigational liver cell infusion to treat urea cycle disorders (UCD) in children. The first patient in the Phase II trial, which will seek to enroll 20 patients in 12 medical centers, is a child with citrullinemia, which is a hereditary UCD. He received six liver cell infusions on six consecutive days at Yale School of Medicine in New Haven, Conn.

15 Apr 2011

Investigational Alzheimer's compounds may treat neuropathies

Drugs already in development to treat Alzheimer's disease may eventually be tapped for a different purpose altogether: re-growing the ends of injured nerves to relieve pain and paralysis.

15 Apr 2011

Halozyme announces Aspart-PH20 study results in type 1 diabetes

Halozyme Therapeutics, Inc. today announced results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 with the active ingredient in NovoLog, accelerates insulin absorption and shortened its duration of action.

15 Apr 2011

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Genzyme Corp., a subsidiary of sanofi-aventis Group, today reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug.

15 Apr 2011

Drug Trial News

African AIDS drug trial stopped prematurely

NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction

Positive interim anemia response data from YM's CYT387 Phase I/II trial in myelofibrosis

Circassia closes $98 million fundraising for lead allergy programmes

Novartis NVA23 Phase III trial in COPD achieves primary end point

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

Japan Tobacco and Torii commence ferric citrate Phase 3 clinical program for hyperphosphatemia

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Positive results from Nabriva's BC-3781 Phase II trial in ABSSSI

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

GRAVITAS study shows no benefit of double-dose compared with standard-dose clopidogrel

Data of ImmunoCellular's lead dendritic cell cancer vaccine candidate for GBM presented at AAN meeting

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

New results from largest multicenter clinical trial for heart transplant patients be released at ISHLT 2011

Opexa's Tovaxin Phase IIb study data in MS presented at AAN meeting

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children

Investigational Alzheimer's compounds may treat neuropathies

Halozyme announces Aspart-PH20 study results in type 1 diabetes

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News